Panacea introduces a novel anti-allergy drug
07 July 2005 | News
Panacea Biotec has launched Ralif (rupatadine 10 mg) a novel
anti-allergy drug for the management of diseases with allergic inflammatory
conditions, such as seasonal and perennial Allergic Rhinitis. According to
Rajesh Jain, joint managing director, Panacea Biotec, "The introduction of
new and novel therapies is an integral part of our continuous effort to provide
innovative yet affordable drug therapies to the ailing humanity. Ralif has a
dual mechanism of action which provides better relief from both allergy and
associated inflammation whereas currently available molecules for Allergic
Rhinitis have antihistaminic property only." Panacea Biotec is one of the
leading health management companies in India involved in the research,
production and marketing of pharmaceuticals, vaccines and biotechnology
products.
